Table S2.

Effect of other factors (than age), on lost to follow-up in the first 36 months after ART initiation (Cox models), for patients 50–59 years while starting ART

Variables	Number of lost to follow-up	Univariable models		Multivariable models
		HR (95% CI)	P-value	HR (95% CI)	P-value
Gender			<0.0001		0.0014
Female	780	1		1
Male	1,022	1.24 (1.13–1.36)		1.17 (1.06–1.29)
Year of ART initiation			<0.0001		<0.0001
<2007	454	1		1
2007–2010	554	0.86 (0.76–0.97)		0.93 (0.82–1.06)
2011 and after	794	1.27 (1.13–1.43)		1.46 (1.28–1.67)
Initial clinical stage			<0.0001		0.01
A,B/I,II	539	1		1
AIDS/III,IV	489	1.08 (0.96–1.23)		1.12 (0.99–1.27)
Missing	774	1.50 (1.34–1.67)		1.20 (1.07–1.35)
Initial CD4 cell count (cells/µL)			<0.0001		<0.0001
≥350	172	1		1
200–349	326	0.94 (0.78–1.13)		1.01 (0.84–1.22)
100–199	334	1.06 (0.88–1.27)		1.16 (0.96–1.40)
50–99	205	1.45 (1.19–1.78)		1.48 (1.20–1.82)
0–49	251	1.54 (1.27–1.87)		1.51 (1.24–1.85)
Missing	514	1.52 (1.28–1.81)		1.28 (1.06–1.54)
Initial hemoglobin (g/dL)			<0.0001		0.0007
≥12	170	1		1
10–12	243	1.03 (0.84–1.25)		1.02 (0.83–1.24)
7.5–10	250	1.56 (1.29–1.90)		1.39 (1.14–1.71)
<7.5	56	1.76 (1.30–2.39)		1.41 (1.03–1.92)
Missing	1,083	1.46 (1.25–1.72)		1.26 (1.05–1.50)
First ART regimen			<0.0001		0.001
AZT+3TC/FTC+NVP/EFV	561	1		1
D4T+3TC/FTC+NVP/EFV	331	0.98 (0.86–1.13)		1.04 (0.90–1.21)
TDF+3TC/FTC+NVP/EFV	299	1.18 (1.03–1.36)		1.02 (0.88–1.18)
Others/unknown	611	1.53 (1.37–1.72)		1.27 (1.12–1.44)
BMI (kg/m2)			<0.0001		<0.0001
18–25	434	1		1
<18	159	1.28 (1.07–1.54)		1.18 (0.98–1.41)
≥25	113	0.81 (0.66–0.99)		0.87 (0.71–1.07)
Missing	1,096	2.06 (1.85–2.31)		2.07 (1.82–2.36)
Total number of patients started ART in 2014–2015 and still in care, in the facility			<0.0001		<0.0001
<500	485	1		1
500–1000	811	0.76 (0.68–0.85)		0.91 (0.81–1.03)
≥1000	506	0.99 (0.87–1.12)		0.68 (0.59–0.78)

Abbreviations: ART, antiretroviral therapy; BMI, body mass index.